Group 1 - The core viewpoint of the article is the strategic collaboration between Liu Pharmaceutical Group and Huawei Technologies, focusing on digital transformation in the pharmaceutical industry and the application of artificial intelligence [1] - The meeting aimed to discuss topics such as supply chain optimization and to further promote the implementation of their strategic partnership [1] - The collaboration seeks to establish a new benchmark for smart pharmaceuticals, indicating a significant shift towards technology integration in the healthcare sector [1]

Group 1 - The core viewpoint of the news is that Liuyao Group's stock has shown positive performance recently, with a notable increase in trading volume and a significant market capitalization of 7.419 billion yuan [1] - As of September 11, Liuyao Group's stock price increased by 2.02% to 18.68 yuan per share, with a trading volume of 1.07 billion yuan and a turnover rate of 1.47% [1] - The company has experienced a year-to-date stock price increase of 9.16%, with a 4.07% rise over the last five trading days and a 14.18% increase over the last 60 days [1] Group 2 - Liuyao Group's main business segments include wholesale (78.16%), retail (15.95%), and industrial (5.47%) operations, with other income contributing 0.42% [1] - As of June 30, the company reported a total revenue of 10.301 billion yuan for the first half of 2025, reflecting a year-on-year decrease of 3.21%, and a net profit attributable to shareholders of 429 million yuan, down 7.52% year-on-year [2] - The company has distributed a total of 1.789 billion yuan in dividends since its A-share listing, with 720 million yuan distributed over the past three years [3] Group 3 - As of June 30, the number of Liuyao Group's shareholders decreased to 32,900, a reduction of 0.89%, while the average number of circulating shares per person increased by 0.90% to 12,056 shares [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 3.2792 million shares, a decrease of 1.1973 million shares compared to the previous period, while Southern CSI 1000 ETF increased its holdings by 0.8512 million shares to 2.9455 million shares [3]

Group 1 - The company announced the public disclosure of the list of incentive objects for the 2025 stock option incentive plan, which was approved in meetings held on August 28, 2025 [1][4] - The public disclosure period for the incentive objects was from August 29 to September 7, 2025, and no objections were received during this period [2][4] - The remuneration committee verified the qualifications of the incentive objects, confirming they met the necessary legal and regulatory requirements [3][6] Group 2 - The company will hold its second extraordinary general meeting of 2025 on September 15, 2025, using a combination of on-site and online voting [9][10] - The meeting will take place at the company's headquarters in Liuzhou, Guangxi, starting at 1:30 PM [11] - Shareholders must register in advance to attend the meeting, with specific registration times and methods outlined [24][25] Group 3 - The company has initiated a share repurchase program, with a total repurchase amount between RMB 100 million and RMB 200 million, and a maximum repurchase price of RMB 25.70 per share [35] - As of September 8, 2025, the company has repurchased 8.1079 million shares, representing 2.04% of the total share capital, with a total expenditure of RMB 148.4649 million [36][37] - The company will continue to comply with relevant regulations during the repurchase process and will disclose updates as necessary [39]

Group 1 - The company has announced the list of participants for its 2025 stock option incentive plan, which was approved by the board and supervisory committee [1][4] - The internal announcement regarding the incentive plan was made from August 29 to September 7, 2025, with no objections received during this period [2][1] - The compensation committee verified the eligibility of the incentive plan participants, confirming they meet the necessary legal and regulatory requirements [3][5] Group 2 - The company has initiated a share repurchase program, with a total repurchase amount set between RMB 100 million and RMB 200 million, and a maximum repurchase price of RMB 25.70 per share [7][9] - As of September 8, 2025, the company has repurchased 8.1079 million shares, representing 2.04% of the total share capital, with a total expenditure of approximately RMB 148.4649 million [9][10] - The company will continue to comply with relevant regulations during the share repurchase process and will disclose updates as necessary [11] Group 3 - The company will hold its second extraordinary general meeting of 2025 on September 15, 2025, utilizing both on-site and online voting methods [13][14] - The meeting will address several proposals that have already been approved by the board and supervisory committee [19][20] - Shareholders must register in advance to attend the meeting, with specific guidelines provided for both on-site and written registration [29][30]

Group 1 - The core point of the article is that Liu Pharmaceutical Group has announced a share buyback plan, with a total of 8.1079 million shares repurchased, representing 2.04% of the company's total share capital as of September 8, 2025 [1] - The share buyback has increased by 0.76% compared to the previous announcement [1] - The highest price for the repurchased shares was 18.60 yuan per share, while the lowest price was 17.83 yuan per share, with a total amount paid of 148.4649 million yuan (excluding transaction fees) [1]

| 证券代码：603368 | 证券简称：柳药集团 公告编号：2025-077 | | --- | --- | | 转债代码：113563 | 转债简称：柳药转债 | 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，在回购期间，回购股份占上市公司总股本的比例 每增加 1%的，应当在事实发生之日起 3 个交易日内予以披露。现将公司回购股份 的进展情况公告如下： 广西柳药集团股份有限公司 关于以集中竞价交易方式回购股份比例达到 2%暨 回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/7/26 | | | | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 2025 7 25 7 | 日~2026 | 年 | 月 | 日 24 | | 预计回购金额 | 10,000万元~20,000万元 | | | | | | 回购用途 | ...

广西柳药集团股份有限公司 2025 年股票期权激励计划激励对象名单 | 16 | 李宏文 | 核心骨干 | 66 | 周健波 | 核心骨干 | | --- | --- | --- | --- | --- | --- | | 17 | 周德荣 | 核心骨干 | 67 | 阳晓菁 | 核心骨干 | | 18 | 谢勇 | 核心骨干 | 68 | 唐桂秀 | 核心骨干 | | 19 | 黄鸿海 | 核心骨干 | 69 | 李霜 | 核心骨干 | | 20 | 谢玉平 | 核心骨干 | 70 | 魏建强 | 核心骨干 | | 21 | 陈玉燕 | 核心骨干 | 71 | 胡龙英 | 核心骨干 | | 22 | 唐锦锋 | 核心骨干 | 72 | 陈飞丽 | 核心骨干 | | 23 | 鲁定琼 | 核心骨干 | 73 | 李玉生 | 核心骨干 | | 24 | 潘俞朴 | 核心骨干 | 74 | 韦盼钰 | 核心骨干 | | 25 | 卢福杏 | 核心骨干 | 75 | 宋宇 | 核心骨干 | | 26 | 高鹏 | 核心骨干 | 76 | 吴晓彤 | 核心骨干 | | 27 | 蒋仕军 | 核心骨干 | 77 | 彭 ...

| 证券代码：603368 | 证券简称：柳药集团 公告编号：2025-076 | | --- | --- | | 转债代码：113563 | 转债简称：柳药转债 | 广西柳药集团股份有限公司 关于召开2025年第二次临时股东会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 广西柳药集团股份有限公司（以下简称"公司"）于 2025 年 8 月 28 日召开第 五届董事会第二十八次会议，审议通过了《关于提请召开 2025 年第二次临时股东会 的议案》，并于 2025 年 8 月 29 日在上海证券交易所网站（www.sse.com.cn）及指定 媒体上披露了《关于召开 2025 年第二次临时股东会的通知》（公告编号：2025-072）， 本次股东大会定于 2025 年 9 月 15 日以现场投票和网络投票相结合的方式召开。 为确保公司股东充分了解本次股东大会的相关信息，现将相关事项提示公告如 下： 一、 召开会议的基本情况 (一) 股东会类型和届次 2025年第二次临时股东会 股东会召开日期：202 ...

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 广西柳药集团股份有限公司（以下简称"公司"）于 2025 年 8 月 28 日召开 第五届董事会第二十八次会议和第五届监事会第二十二次会议，分别审议通过了 《关于<广西柳药集团股份有限公司 2025 年股票期权激励计划（草案）及其摘要> 的议案》等相关议案。根据《上市公司股权激励管理办法》（以下简称"《管理办 法》"）等相关规定，公司对 2025 年股票期权激励计划（以下简称"本激励计划"） 激励对象的姓名和职务在公司内部进行了公示。公司董事会薪酬与考核委员会 （以下简称"薪酬委员会"）结合公示情况对激励对象名单进行了核查，相关公 示情况及核查情况如下： 一、公示情况及核查方式 1、公司对激励对象的内部公示情况 （1）公示内容：本激励计划激励对象的姓名及职务 （2）公示期间：2025 年 8 月 29 日至 2025 年 9 月 7 日（共计 10 日） | 证券代码：603368 | 证券简称：柳药集团 | 公告编号：2025-075 | | --- | --- | -- ...

Group 1 - The core point of the article is that Liu Pharmaceutical Group (603368.SH) has repurchased a total of 8.1079 million shares, which accounts for 2.04% of the company's total share capital as of September 8, 2025, indicating an increase of 0.76% compared to the previous announcement [1] - The highest price for the repurchased shares was 18.60 CNY per share, while the lowest price was 17.83 CNY per share [1] - The total amount paid for the repurchased shares was 148.4649 million CNY, excluding transaction fees [1]